NASDAQ:VERU
An interesting stock to watch.
The asset is in a 1,5 month uptrend without major pullbacks + MACD Crossover indicator's Long signal is still in progress.
The buy zone is marked out, targets are 12.5, 15, 18, 23,88 and towards the all-time high.
Invalidation: closing below the gap.
Disclaimer: This article should not be considered as financial or...
VERU is consolidating and i am liking this chart alot. The MACD is in red still and will wait to get in once i see the MACD closing red. Give this a week to play out. Not a financial advisor.
VerU finally made its move today,
tomorrow we will look for a move above the Fibonacci Golden pocket @ $10.16
Target is back to the ATH @ $11.45
Potential resistance $10.98
VERU may offer the potential for a reversal trade as it
bounces off GAP up and Yearly candle support.
MA's have caught to provide support.
Selling volume has declined considerably.
The pumpers and misguided late comers may have exited.
Potential entry above $9.15
Targets as per Fibonacci retracement levels.
VERU is an oncology bio pharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer. It announced the presentation of pre-clinical data demonstrating the efficacy of oral VERU-111 in the treatment of human derived animal models of triple negative breast cancer. VERU reported on 12/9/20 Q4 earnings loss of...
Company details
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of...
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration...
